New psoriasis drug matches leading biologic in Head-to-Head trial

NCT ID NCT06398652

Completed Disease control Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested whether a new biologic called CMAB015 works as well as secukinumab (Cosentyx) for moderate-to-severe plaque psoriasis. 336 adults received either drug for up to 48 weeks. The main goal was to see if at least 75% of skin symptoms improved by week 12. The study is now complete, but results have not yet been shared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CMAB015 (a biologic similar to secukinumab)
What this could lead to: If CMAB015 works as well as secukinumab, it could offer a more affordable or accessible treatment option for people with moderate-to-severe psoriasis.
What could go wrong: This is a comparison study, not a test of a new cure. Even if CMAB015 is similar, it may not be approved or may have different side effects. The results are not yet published.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Show contact details

Locations

Huashan Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.